BioCentury
ARTICLE | Financial News

Odonate proposes $172.5M IPO

November 17, 2017 9:20 PM UTC

On Nov. 13, cancer company Odonate Therapeutics LLC (San Diego, Calif.) proposed to raise up to $175.5 million in an IPO on NASDAQ underwritten by Goldman Sachs, Cowen and Jefferies.

This quarter, Odonate plans to begin the Phase III CONTESSA trial of lead candidate tesetaxel in patients with locally advanced or metastatic breast cancer. Top-line data are expected in 2020. Tesetaxel is an oral semi-synthetic taxane derivative...